Cipla faces headwinds but remains resilient with strong product portfolio, robust earnings growth potential, and reasonable ...

Cipla has announced an exclusive licensing agreement with Taiwan-based Formosa Pharmaceuticals to market clobetasol ...

Cipla Ltd is one of the leading pharmaceutical companies in India. The Company is in the business of manufacturing developing and marketing wide range of branded and generic formulations and Active ...

Here are the local and international drugmakers also eyeing the Indian market and looking to introduce rivals to Lilly's drug ...

Eli Lilly on Thursday launched in India its diabetes and weight-loss drug, Mounjaro, which has already clocked in over $20 ...

Bonus Oct 18, 1999 Nov 05, 1999 Oct 07, 1999 Bonus Ratio: 2 share(s) for every 1 shares held Rights Feb 03, 1995 Mar 02, 1995 May 03, 1995 Rights ratio: 4 share for every 50 held at a price of Rs ...

Siddharth Sedani of Anand Rathi Shares & Stock Brokers recommends buying BEL shares for a short-term target of Rs 305 and a ...

The company's shares climbed over 4% on the BSE. Jan 28, 2025 14:20 Cipla Launches Asthma Screening App in India Cipla has launched a mobile application, CipAir, to aid in asthma screening in India, ...

Formosa Pharmaceuticals and Cipla Limited have entered into an exclusive licensing agreement for the commercialization of ...

The drug will be priced at ₹3,500 for a 2.5 mg vial and ₹4,375 for the 5 mg vial. The injectable, to be taken once a week, ...

Cipla's shares are currently priced at Rs 1524.20, reflecting a daily change of 0.81% and a weekly return of 3.89%. Cipla's stock is currently at Rs 1520.25, showing a slight uptick of 0.55% today, ...